

Scottsdale Offices & Laboratory

As of October 6, 2026, Castle Biosciences, a long-time resident of Phoenix, Arizona, is moving its laboratory operations into a new, expanded facility in Scottsdale at [Two Scottsdale Landing, 8667 E. Hartford Drive](#).

Situated within the [260-acre Perimeter Center business park](#), the [new 55,000-square-foot office and laboratory](#) significantly expand Castle's operational footprint to accommodate growing test volumes and support the company's long-term growth. Features of the new facility include:

- [New infrastructure](#) to better support operations, including new HVAC systems, IT infrastructure, security systems, a whole laboratory UPS (Uninterruptible Power Supply), and a new generator that doubles the facility's [power redundancy](#);
- Floor-to-ceiling windows to maximize [natural light](#), with [views](#) of the McDowell Mountains;
- A [fitness center](#) with locker rooms;
- [Walking trails](#) throughout the business park;
- An onsite third-party [café](#) offering convenient grab-and-go options;
- A ground-level landscaped [courtyard](#) with seating, Wi-Fi, and outdoor games;
- A second-level tenant [collaboration lounge/gameroom](#) with flat-screen TVs, a pool table, ping pong, and table games;
- [Convenient access](#) to Scottsdale Quarter, Kierland Commons, and various lodging, dining, and entertainment venues.



About Castle

- Castle Biosciences is a [leading molecular diagnostics company](#) focused on improving health through innovative tests that guide patient care.
- Castle is [headquartered in Friendswood, Texas](#) (a suburb of Houston) and in addition to the new [Scottsdale facility](#), operates [clinical laboratories](#) in [Phoenix](#) and [Pittsburgh](#).
- As of June 30, 2026, Castle employs [more than 1,000 employees](#) across the U.S., with approximately 220 of those employees based in the Phoenix/Scottsdale area.
- Castle is publicly traded on the Nasdaq exchange ([CSTL](#)). 2025 total revenue was [\\$344 million](#), and cash, cash equivalents and marketable securities were [~\\$267 million](#) (as of 6/30/2026).
- For its core revenue drivers, [DecisionDx®-Melanoma](#) and [TissueCypher®](#), Castle delivered [78,097 total test reports](#) in 2025, an [increase of 37%](#) compared to 2024.
- Castle markets [six proprietary tests](#) designed to answer clinical questions and address treatment plan challenges in dermatology, uveal melanoma, and Barrett's esophagus.

DERMATOLOGY

DecisionDx
•Melanoma.

Provides personalized risk assessment to inform decisions and improve outcomes for patients with cutaneous melanoma

DecisionDx
•SCC.

Provides individualized metastatic and local recurrence risk and likelihood of benefit from adjuvant radiation therapy for high-risk squamous cell carcinoma

MyPath
•Melanoma.

Aids in the diagnosis and management decisions for patients with ambiguous melanocytic lesions

AdvanceAD
•Tx™

Guides systemic treatment decision making in patients with moderate-to-severe atopic dermatitis

UVEAL MELANOMA

DecisionDx
•UM.

Predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer

BARRETT'S ESOPHAGUS

TissueCypher
•Barrett's Esophagus.

Predicts progression to esophageal cancer in patients with Barrett's esophagus